{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-002499","form_type":"8-K","ticker":"HBIO","cik":"0001123494","company_name":"HARVARD BIOSCIENCE INC","filed_at":"2023-04-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.997744+00:00","generated_at":"2026-06-16T15:31:31.486590+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Harvard Bioscience Q1 revenue $30M (+4% YoY); net income $0.6M vs $6.9M loss; adj EBITDA margin 16%","bullets":["Q1 revenues $30.0M, up 4% from $28.8M in Q1'22; gross margin improved to 61% from 56%.","GAAP net income $0.6M ($0.01 diluted EPS) vs net loss of $6.9M ($0.17 loss) in Q1'22.","Adjusted EBITDA $4.8M (16% margin) vs $2.7M (9% margin) in prior year.","Paid down debt by $2.8M; net debt $41.0M; targeting net leverage ~2x by year-end.","Full-year 2023 guidance: mid-single digit revenue growth, gross margins ~60%, adjusted EBITDA margins 16-17%."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-002499","json":"https://secwatch.observer/filing/0001171843-23-002499.json","markdown":"https://secwatch.observer/filing/0001171843-23-002499.md","text":"https://secwatch.observer/filing/0001171843-23-002499.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1123494/000117184323002499/0001171843-23-002499-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1123494/000117184323002499/f8k_042523.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T15:31:31.486590+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"be092a56818dd66f9a28fe6e8cfc0dedfc38ffa5","claim":"HARVARD BIOSCIENCE INC reported first quarter ended March 31, 2023 results: revenue $30.0 million, net income $0.6 million, EPS $0.01. Guidance initiated.","evidence_excerpt":"a filing. --- EX-99.1 (EXHIBIT 99.1) --- EX-99.1 2 exh_991.htm EXHIBIT 99.1 Exhibit 99.1 Harvard Bioscience Announces First Quarter 2023 Financial Results • Q1 Revenues of $30 million up 4% over prior year period • Q1 GAAP Operating Income of $1.7 million up from a loss of $6.7 million prior year • Q1 Adjusted Operating Income of $4.4 million up from $2.4","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1123494/000117184323002499/0001171843-23-002499-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Revenue","value":"$30.0 million"},{"label":"Net income","value":"$0.6 million"},{"label":"EPS","value":"$0.01"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}